Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
03 juin 2024 09h30 HE
|
Ori Biotech Ltd
Ori Biotech and CTMC announce promising results for IRO, Ori’s newly launched next-generation CGT manufacturing enabling platform.
Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
29 mai 2024 15h30 HE
|
Ori Biotech Ltd
Ori Biotech announces the commercial launch of IRO, a next-generation platform built to overcome the challenges of cell therapy manufacturing, at ISCT 2024
Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari
15 nov. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players -...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
24 avr. 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12 avr. 2022 13h53 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
27 janv. 2021 20h30 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals
27 oct. 2020 08h30 HE
|
Predictive Oncology
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDAQ: POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an...
Global Cancer Stem Cell Market to Reach Nearly $2B by 2022
17 janv. 2018 12h29 HE
|
BCC Research
WELLESLEY, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Cancer stem cells have been found in a range of human tumors and are potential targets for cancer treatment. The global cancer stem cell...